Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort - Scorecard - MDSpire

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort

  • By

  • Roberta Elisa Rossi

  • Matteo Ferraris

  • Lorenzo Petronio

  • Benedetta Masoni

  • Luca Di Stefano

  • Alexia Francesca Bertuzzi

  • Sara Fraticelli

  • Andrea Gerardo Antonio Lania

  • Alessandro Zerbi

  • Cesare Hassan

  • Alessandro Repici

  • July 7, 2026

  • 0 min

Share

Clinical Scorecard: Clinical and Histological Factors Linked to the Development of Type 1 Gastric Neuroendocrine Tumors in Patients with Autoimmune Atrophic Gastritis: Findings from a Real-World Study

At a Glance

CategoryDetail
ConditionType 1 Gastric Neuroendocrine Tumors (T1gNETs)
Key MechanismsChronic inflammation and ECL cell hyperplasia associated with autoimmune atrophic gastritis (AIG)
Target PopulationPatients with autoimmune atrophic gastritis (AIG)
Care SettingGastroenterology and Endoscopy Unit

Key Highlights

  • 16% of AIG patients diagnosed with T1gNETs
  • ECL cell hyperplasia is a significant histological factor for T1gNETs
  • Dyspeptic symptoms inversely correlated with T1gNET occurrence
  • No significant predictive value found for smoking, alcohol, or BMI
  • Asymptomatic patients more likely to develop T1gNETs

Guideline-Based Recommendations

Diagnosis

  • Histological confirmation of AIG based on gastric atrophy and intestinal metaplasia

Management

  • High-quality endoscopic follow-up every 3 years for AIG patients

Monitoring & Follow-up

  • Use of serum biomarkers like chromogranin A (CgA) and gastrin, though predictive ability is inconclusive

Risks

  • Increased risk of T1gNETs and gastric adenocarcinoma in AIG patients

Patient & Prescribing Data

Adults (≥18 years) with histologically confirmed AIG

Further data needed for personalized endoscopic surveillance protocols

Clinical Best Practices

  • Regular monitoring of AIG patients for T1gNETs
  • Consideration of histological factors like ECL hyperplasia in risk assessment

Related Resources & Content

Original Source(s)

Related Content